Abstract |
The involvement of two phenotypically different regulatory T cells in different stages of tumor growth was investigated. Treatment of BALB/c mice with anti-CD25 monoclonal antibody (mAb) (PC61), but not anti-CD4 mAb (GK1.5) before RL male 1 or Meth A inoculation caused tumor rejection. On the other hand, treatment of BALB/c mice with anti-CD4 mAb (GK1.5) but not anti-CD25 mAb (PC61) on day 6 after inoculation of the same tumors caused rejection. The findings suggest that CD4+CD25+ T cells downregulated the rejection response in the early stage of tumor growth. On the other hand, putative CD4+CD25- T cells downregulated the tumor rejection response in the late stage. Both CD4+CD25+ and putative CD4+CD25- T cells appeared to inhibit the efficient generation of cytotoxic T lymphocytes (CTL). The present study also demonstrated that the treatment of BALB/c mice with anti-CD25 mAb (PC61) at 4 or 6 weeks after 3-methylcholanthrene (3-MC) inoculation retarded tumor occurrence and prolonged survival.
|
Authors | Isao Tawara, Yutaka Take, Akiko Uenaka, Yuji Noguchi, Eiichi Nakayama |
Journal | Japanese journal of cancer research : Gann
(Jpn J Cancer Res)
Vol. 93
Issue 8
Pg. 911-6
(Aug 2002)
ISSN: 0910-5050 [Print] Japan |
PMID | 12716469
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal
- Carcinogens
- Receptors, Interleukin-2
- Methylcholanthrene
|
Topics |
- Animals
- Antibodies, Monoclonal
(metabolism)
- CD4-Positive T-Lymphocytes
(metabolism, pathology)
- Carcinogens
- Cell Division
- Down-Regulation
- Flow Cytometry
- Male
- Methylcholanthrene
- Mice
- Mice, Inbred BALB C
- Neoplasm Transplantation
- Neoplasms
(chemically induced)
- Neoplasms, Radiation-Induced
(pathology)
- Receptors, Interleukin-2
(physiology)
- T-Lymphocytes, Cytotoxic
(metabolism)
- Time Factors
- Tumor Cells, Cultured
|